Special Issue

Targeted Therapy and Biomarkers for Solid Tumors

Message from the Guest Editors

Targeted therapy emerged in the late 20th century, revolutionizing cancer treatment by focusing on specific molecular targets associated with cancer growth and progression. The discovery and validation of biomarkers have been pivotal in tailoring these therapies to individual patients. This Special Issue aims to explore the latest developments in targeted therapies and biomarker research for solid tumors. It seeks to highlight innovative approaches, from molecular mechanisms to clinical applications, that contribute to personalized cancer treatment. We are interested in research that delves into the discovery of novel biomarkers, mechanisms of resistance to targeted therapies, and the development of new therapeutic agents. Studies that integrate multi-omics data and translational research are particularly encouraged. We welcome original research articles and comprehensive reviews that address any aspect of targeted therapy and biomarker discovery in solid tumors. Submissions focusing on clinical trials, mechanistic studies, and technological advancements in this field are highly valued.

Guest Editors

Dr. Anca Zgură

Department of Oncology-Radiotherapy, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania

Prof. Dr. Rodica Maricela Anghel

Department of Oncology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Str, 030167 Bucharest, Romania

Deadline for manuscript submissions

25 December 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/211750

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

